A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs AB 122 (Primary) ; AB-680 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastrointestinal cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 14 Nov 2019 Status changed from not yet recruiting to recruiting.
- 24 Sep 2019 Status changed from planning to not yet recruiting.
- 06 Aug 2019 According to an Arcus Biosciences media release, the company received IND clearance to initiate this phase 1/1b trial.